live discussion: Rituxan/rituximab

Dr. Rohit Aggarwal will answer your questions on Friday, June 20, at 3pm ET (1PM for us in Mountain!) about rituximab (Rituxan), which was the subject of a multi-center trial that included both adults and children.  Rituximab is used to treat dermatomyositis and polymyositis.

Dr. Aggarwal is an assistant professor in the Division of Rheumatology at the University of Pittsburgh, and a member of TMA’s medical advisory board. He is also a member of the international working group that is collaborating on finding standards of improvement for myositis research.

 

TMA members are invited to submit questions in advance of the chat.
You MUST be logged in to submit a question. To login go to http://www.myositis.org. Sign in is at the right hand corner.

When submitting questions, please be as brief as possible. If you have more than one question, submit them separately in the question window. Questions that are off-topic will not be answered.

Live discussions are a benefit of membership in TMA. If you’re not already a member, become a TMA member today to take advantage of Q & A sessions as well as many other member benefits. Membership is free.
The discussion transcript will be available immediately following the Q & A session. Visit the Live Discussion page under Community on the TMA homepage to view a complete list of past transcripts and upcoming discussions.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s